Deubiquitinase inhibition as a cancer therapeutic strategy.
about
Insights into APC/C: from cellular function to diseases and therapeuticsDUBs, New Members in the Hypoxia Signaling clUbControlling DNA-End Resection: An Emerging Task for Ubiquitin and SUMOTargeting Pink1-Parkin-mediated mitophagy for treating liver injurySerum and urine biomarkers for human renal cell carcinomaSynthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15Deubiquitinases (DUBs) and DUB inhibitors: a patent reviewPlatinum-containing compound platinum pyrithione suppresses ovarian tumor proliferation through proteasome inhibitionOverexpression of ubiquitin specific peptidase 14 predicts unfavorable prognosis in esophageal squamous cell carcinoma.Deubiquitinase OTUD6B Isoforms Are Important Regulators of Growth and Proliferation.Anti-infective Activity of 2-Cyano-3-Acrylamide Inhibitors with Improved Drug-Like Properties against Two Intracellular Pathogens.Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.Involvement of USP24 in the DNA damage response.The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cellsTargeting ubiquitination for cancer therapies.Deubiquitylating enzyme, USP9X, regulates proliferation of cells of head and neck cancer lines.Chemical and semisynthetic approaches to study and target deubiquitinases.The ubiquitin-proteasome system and chromosome 17 in cerebellar granule cells and medulloblastoma subgroups.Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability.The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.The Emerging Role of Non-traditional Ubiquitination in Oncogenic Pathways.The importance of regulatory ubiquitination in cancer and metastasis.Activity-based probes for the ubiquitin conjugation-deconjugation machinery: new chemistries, new tools, and new insights.Proteome Profiling of Urinary Exosomes Identifies Alpha 1-Antitrypsin and H2B1K as Diagnostic and Prognostic Biomarkers for Urothelial Carcinoma.Essential role of HCMV deubiquitinase in promoting oncogenesis by targeting anti-viral innate immune signaling pathways.Uncovering the role of USP54 in cancer.The deubiquitinating enzyme USP5 promotes pancreatic cancer via modulating cell cycle regulators.USP51 promotes deubiquitination and stabilization of ZEB1.Thiolutin is a zinc chelator that inhibits the Rpn11 and other JAMM metalloproteases.Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents.Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers.UCHL5 expression associates with improved survival in lymph-node-positive rectal cancer.Nuclear ubiquitin C-terminal hydrolase L5 expression associates with increased patient survival in pancreatic ductal adenocarcinoma.Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7.Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing.Discovery and characterization of highly potent and selective allosteric USP7 inhibitors.Deubiquitylating enzymes and drug discovery: emerging opportunities.Targeting Deubiquitinating Enzymes and Autophagy in Cancer.Evidence for the ISG15-Specific Deubiquitinase USP18 as an Antineoplastic Target.
P2860
Q26740196-E69B9101-214C-4C90-8623-52E0E9C55042Q26750882-7D3E1D9B-9A46-48EE-8E61-CEC21028BE4CQ28069597-4F94657F-4328-476D-BCD8-593481BD2E23Q28082937-27678DCA-0E1B-4C70-A360-BCFFBACC9338Q28084949-EBF9F488-2E91-406E-8C06-B702856797FFQ28834132-CDBF9B77-BF62-4444-B001-1D74353FBFFDQ28834608-966B0E57-2590-4C38-B911-849D58933BF4Q33801982-27F20AD6-9072-4AC0-8814-85334E6606B0Q33863380-E5518F28-2A19-4578-8000-3A371564026EQ34545092-D38F2F07-4662-437B-909B-126A2A87BFFDQ36006797-FF474B19-A60F-44CA-AA51-A4B12490FE7CQ36132338-39AF60A4-CD37-4BD4-9C19-FC053820EA19Q36771950-51F520B7-CADA-4CB2-B022-CC9672874B03Q36836107-42B56850-AEEE-47F2-AC3C-DD14891FE730Q36970245-53E2D78F-FDD3-4A59-A1C5-AACA5F6653DCQ37158445-C4D6C8B1-862F-44E4-BEE6-511DA4408614Q38760064-CC71C766-211F-44E2-A778-E9E185AC55E4Q38799376-362D9E5D-F21F-48C6-B009-4DEC13B4C694Q38945828-9E673C98-802E-40BA-9988-1FC1BDFC43DFQ38972458-FE2AAA9D-5274-43C2-9715-64758BA4C340Q39029195-9C4E5B8F-A02C-45E2-A01D-5AD8F1416F1EQ39116600-330C7F65-8BA3-43D6-8A8A-71B21209467EQ39122602-E5475910-2AE1-46F5-9DF5-8ECAAEF0E459Q39135148-8E421B3A-891C-4CAF-AD59-B730C40CCDA0Q41238990-C2C10CB6-3743-4ECD-AB35-9450C5ADE401Q41923781-AF971CC5-D94A-4037-ACBA-AA9BD1B484D9Q42315748-7F1E37E5-A145-4AB3-8C93-924F229FFBECQ42371622-2B8BF115-7288-4BDD-B27F-67D3F7B79CFDQ43525541-FABA990C-960A-47FB-A1D0-9F95DFBA3070Q46325214-C1FD7A2A-F277-494D-BAC3-D610759F6CA7Q47098444-C1712A70-9E80-44D1-B9A3-8C796BF553C4Q47100164-DFD619FB-13A4-4B41-9AC0-13F5F82CEE54Q47328929-80176A1A-A923-47A2-9968-53D9712EC808Q47336139-C121B161-F2D4-46F9-8D94-67BFEE3DE0F0Q47619828-7A1B3459-9286-41BD-AA20-F0F9DEEF987AQ47631097-3B952308-B5CC-4B70-8FE6-92E68C7D0E96Q48188572-0C472AFE-C24A-4620-93E5-AB1B342DE92AQ48265884-80C7921F-8EFD-4591-8DC0-F7399CD84825Q48945410-13EEEBF9-859D-4824-B3BC-D6A7D3E4D3DFQ49990366-17518F1D-9853-42D1-9A74-8224283A9F3F
P2860
Deubiquitinase inhibition as a cancer therapeutic strategy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Deubiquitinase inhibition as a cancer therapeutic strategy.
@en
type
label
Deubiquitinase inhibition as a cancer therapeutic strategy.
@en
prefLabel
Deubiquitinase inhibition as a cancer therapeutic strategy.
@en
P1476
Deubiquitinase inhibition as a cancer therapeutic strategy.
@en
P2093
Padraig D'Arcy
P356
10.1016/J.PHARMTHERA.2014.11.002
P50
P577
2014-11-06T00:00:00Z